Hetrombopag
- Generic Name
- Hetrombopag
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C25H22N4O5
- CAS Number
- 1257792-41-8
- Unique Ingredient Identifier
- 9WGT51BDDL
- Background
Hetrombopag is under investigation in clinical trial NCT03976882 (Hetrombopag for the Treatment of Chemotherapy-induced Thrombocytopenia in Subjects With Malignancy.).
- Associated Conditions
- -
- Associated Therapies
- -
Clinical Study on Efficacy and Safety of Hetrombopag in the Preoperative Patients of Thrombocytopenia
- First Posted Date
- 2024-08-20
- Last Posted Date
- 2024-08-20
- Lead Sponsor
- The Third People's Hospital of Chengdu
- Target Recruit Count
- 55
- Registration Number
- NCT06562738
- Locations
- 🇨🇳
Chengdu Third People's Hospital, Chengdu, Sichuan, China
The Efficacy and Safety of Hetrombopag as Secondary Prevention to Chemotherapy-induced Thrombocytopenia in Patients With Gynecologic Malignancies
Phase 2
Not yet recruiting
- Conditions
- Interventions
- First Posted Date
- 2023-10-25
- Last Posted Date
- 2023-10-25
- Target Recruit Count
- 48
- Registration Number
- NCT06099925
The Efficacy and Safety of Hetrombopag in Primary Prevention of Thrombocytopenia Induced by the Niraparib Maintenance in Advanced Ovarian Cancer Patients
- First Posted Date
- 2023-09-14
- Last Posted Date
- 2023-09-14
- Target Recruit Count
- 34
- Registration Number
- NCT06036966
Hetrombopag in Secondary Prevention of XPO-1 Inhibitor-induced Thrombocytopenia in Lymphoma
Phase 2
Not yet recruiting
- Conditions
- Interventions
- First Posted Date
- 2023-08-01
- Last Posted Date
- 2023-09-06
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 90
- Registration Number
- NCT05969158
Hetrombopag for the Treatment of Chemotherapy-Induced Thrombocytopenia in Adults With Solid Tumors.
Phase 3
Not yet recruiting
- Conditions
- Interventions
- First Posted Date
- 2023-05-18
- Last Posted Date
- 2023-05-18
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 192
- Registration Number
- NCT05864014
Hetrombopag for the Enhancement of Platelet Engraftment After Allogeneic Hematopoietic Stem Cell Transplantation
Not Applicable
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2023-02-14
- Last Posted Date
- 2023-02-14
- Target Recruit Count
- 78
- Registration Number
- NCT05727917
- Locations
- 🇨🇳
Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences, Tianjin, Tianjin, China
Efficacy and Safety of Herombopag in Patients With Thrombocytopenia Before Hepatectomy
- First Posted Date
- 2022-07-05
- Last Posted Date
- 2024-03-13
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 96
- Registration Number
- NCT05442632
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, China
A Clinical Study of Hetrombopag Olamine Tablets for Thrombocytopenia Induced by Chemotherapy in Advanced Breast Cancer
- First Posted Date
- 2022-05-27
- Last Posted Date
- 2024-03-04
- Lead Sponsor
- Henan Cancer Hospital
- Target Recruit Count
- 60
- Registration Number
- NCT05394285
- Locations
- 🇨🇳
Henan Cancer Hospital, Zhengzhou, China
Hetrombopag for Lower-risk MDS With Thrombocytopenia: a Prospective，Open-label, Single-arm Study.
- First Posted Date
- 2022-05-26
- Last Posted Date
- 2022-05-26
- Lead Sponsor
- Tongji Hospital
- Target Recruit Count
- 28
- Registration Number
- NCT05392647
An Observational, Multicenter Study to Evaluate the Safety and Effectiveness of Hetrombopag in Patients With ITP or AA
Not yet recruiting
- Conditions
- Interventions
- First Posted Date
- 2022-04-19
- Last Posted Date
- 2022-04-19
- Lead Sponsor
- Wuhan Union Hospital, China
- Target Recruit Count
- 1150
- Registration Number
- NCT05333861
- Locations
- 🇨🇳
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath